Biosidus Strengthens Global Presence with Mubadala Bio Partnership in UAE
In a significant move aimed at expanding its international reach, Biosidus, a notable player in Latin America's biotechnology sector, has officially signed a licensing and supply agreement with Mubadala Bio, the life sciences platform of Mubadala Investment Company. This partnership marks a pivotal step forward in bringing a diverse array of biologic therapies to the United Arab Emirates (UAE). The agreement was finalized during the BIO International Convention 2026, a prestigious venue for life sciences discussions, and was witnessed by Dr. Noura Al Ghaithi, Undersecretary of the Department of Health in Abu Dhabi.
This collaboration is set to encompass biologic therapies in critical fields such as endocrinology, nephrology, and oncology, featuring key products including epoetin alfa, filgrastim, interferon beta, and somatropin. The introduction of these therapies will not only enhance patient care in the UAE but also align with the regional healthcare objectives to localize essential medicines.
Hamad Almarzooqi, Group Deputy CEO of Mubadala Bio, emphasized the importance of strategic partnerships in advancing the accessibility of vital medications. He remarked, "Through our collaboration with Biosidus, we are increasing access to biologic therapies in the UAE while advancing our commitment to local pharmaceutical manufacturing."
In response, Mariano de Elizalde, CEO of Biosidus, expressed his enthusiasm for the partnership, stating, "We are honored to partner with Mubadala Bio in support of its mission to strengthen healthcare resilience and expand access to advanced biologic therapies in the UAE. This agreement represents an important milestone in Biosidus' international growth strategy and reflects our shared commitment to innovation, quality and patient access."
This strategic alliance adds a significant international partner for Biosidus, underlining its commitment to supporting healthcare systems and life sciences organizations in both emerging and developed markets. The partnership with Mubadala Bio is expected to facilitate the development of vital health solutions tailored to meet local needs, thereby contributing not only to the healthcare environment but also to the economy of the UAE.
Biosidus stands out as one of the pioneering biotechnology firms in Latin America, headquartered in Argentina, with a presence in over 50 countries globally. With more than four decades of experience, the company specializes in the development, manufacturing, and commercialization of biologic therapies, gaining recognition for its expertise in complex biologics, biosimilars, and technology transfer projects. This partnership is a testament to Biosidus’ intent to foster innovation in healthcare and to leverage its extensive experience to fill therapeutic gaps in various markets.
Mubadala Bio, as a cornerstone of Mubadala Investment Company, is dedicated to creating impactful healthcare outcomes not only in the UAE but regionally and beyond. Their strategic role in strengthening national drug security and enhancing access to essential therapies ensures that the partnership with Biosidus will be instrumental in achieving these goals. In conclusion, as Biosidus takes this bold step into the UAE market, it reinforces its vision for international expansion, aiming to provide innovative health solutions that improve patient outcomes across diverse demographics.
This collaboration is set to encompass biologic therapies in critical fields such as endocrinology, nephrology, and oncology, featuring key products including epoetin alfa, filgrastim, interferon beta, and somatropin. The introduction of these therapies will not only enhance patient care in the UAE but also align with the regional healthcare objectives to localize essential medicines.
Hamad Almarzooqi, Group Deputy CEO of Mubadala Bio, emphasized the importance of strategic partnerships in advancing the accessibility of vital medications. He remarked, "Through our collaboration with Biosidus, we are increasing access to biologic therapies in the UAE while advancing our commitment to local pharmaceutical manufacturing."
In response, Mariano de Elizalde, CEO of Biosidus, expressed his enthusiasm for the partnership, stating, "We are honored to partner with Mubadala Bio in support of its mission to strengthen healthcare resilience and expand access to advanced biologic therapies in the UAE. This agreement represents an important milestone in Biosidus' international growth strategy and reflects our shared commitment to innovation, quality and patient access."
This strategic alliance adds a significant international partner for Biosidus, underlining its commitment to supporting healthcare systems and life sciences organizations in both emerging and developed markets. The partnership with Mubadala Bio is expected to facilitate the development of vital health solutions tailored to meet local needs, thereby contributing not only to the healthcare environment but also to the economy of the UAE.
Biosidus stands out as one of the pioneering biotechnology firms in Latin America, headquartered in Argentina, with a presence in over 50 countries globally. With more than four decades of experience, the company specializes in the development, manufacturing, and commercialization of biologic therapies, gaining recognition for its expertise in complex biologics, biosimilars, and technology transfer projects. This partnership is a testament to Biosidus’ intent to foster innovation in healthcare and to leverage its extensive experience to fill therapeutic gaps in various markets.
Mubadala Bio, as a cornerstone of Mubadala Investment Company, is dedicated to creating impactful healthcare outcomes not only in the UAE but regionally and beyond. Their strategic role in strengthening national drug security and enhancing access to essential therapies ensures that the partnership with Biosidus will be instrumental in achieving these goals. In conclusion, as Biosidus takes this bold step into the UAE market, it reinforces its vision for international expansion, aiming to provide innovative health solutions that improve patient outcomes across diverse demographics.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.